Phase II studies of gemcitabine for non-small cell lung cancer in Japan.

@article{Fukuoka1997PhaseIS,
  title={Phase II studies of gemcitabine for non-small cell lung cancer in Japan.},
  author={Masahiro Fukuoka and Masahiro Takada and Akira Yokoyama and Yuzo Kurita and Hisanobu Niitani},
  journal={Seminars in oncology},
  year={1997},
  volume={24 2 Suppl 7},
  pages={S7-42-S7-46}
}
To determine the activity and toxicity of gemcitabine (2',2'-difluorodeoxycytidine), three phase II single-agent studies have been conducted in patients with non-small cell lung cancer in Japan. In an early phase II study, 17 previously treated and 47 untreated patients were treated with gemcitabine. Gemcitabine was given intravenously at a dose of 800 mg/m2 or 1,000 mg/m2 once a week for 3 weeks followed by a week of rest, repeating every 4 weeks. Although none of the patients with prior… CONTINUE READING